Search Results

We hope you find what you’re looking for. You can email us if you need additional help.

Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

VANCOUVER, BC – April 23, 2024 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied

April 23, 2024

Optimi Health Corp.

21 Water St #600, Vancouver, BC V6B 1A1

Contact Information

E: investors@optimihealth.ca

T: +778-761-4551

Regulator Filings

Sedar Documents

Sedar Profile

Reporting – Modern Slavery Report 2024

Legal Counsel: Norton Rose Fulbright

Auditor: Smythe CPA

Transfer Agent: Endeavor Trust

Corporate Visibility & Investor Relations: Kydder Group

Trading Symbol: CSE: OPTI | OTC:OPTHF |

FRA: 8BN

CUSIP Number: 68405H100

ISIN Number: CA68405H1001

WKN: A2QQEL

Issued & Outstanding: (30/06/2022) 80,451,883

Incorporated: BC / May 27, 2020

Year End: September 30th

Privacy

Disclaimer

Product Disclaimer: Optimi Health products are still being investigated through a clinically validated development program for the purpose of applying for market authorization.

The safety and efficacy of our products has not been formally established.

Search Results

Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

Visit OptimiLife.com

Get news & updates directly to your inbox.

Interested In Optimi? Let's Talk.